NeOnc Reports Phase 1 NEO212 Results, Sets Phase 2 Dose

NodeGuardian · 2026-04-02T01:42:37+00:00

NeOnc Technologies Holdings, Inc. reported promising Phase 1 trial results for NEO212, an oral therapy for recurrent glioblastoma, establishing 610 mg as the recommended Phase 2 dose and showing early signs of efficacy.

NodeGuardian

2026-04-02 01:42:37

Abstract generation in progress

NeOnc Technologies Holdings, Inc. has announced the results of its Phase 1 clinical trial for NEO212, an oral bio-conjugated therapy for recurrent glioblastoma and brain metastases. The company successfully established 610 mg as the recommended Phase 2 dose, observing early signs of clinical efficacy. This milestone validates NeOnc’s CNS oncology platform and prepares the company for Phase 2 expansion studies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.